PG
Pushkal Garg (EVP Chief R&D) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $1.4M of ALNY (4,360 sh across 3 lots, as filed), executed Feb 27. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
4
0 buys · 4 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$4.1M
shares × price, as filed
Last traded
Mar 5
Filed Mar 6
Median ADV $470.9M across their filed names
Open performance→Volume by month
Buys $0
Sells $26.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
4 filings
Sector per market data · by filing · past 12 months
Most traded names
ALNYRecent filings
ALNYSALE
Alnylam Pharmaceuticals, Inc.
View filing →
$216K862 sh × $250.11
Exec Feb 18 2025
Filed Feb 18 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $15.0M
52,592 sh × $285.00
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $302K
1,204 sh across 2 lots
Exec Dec 12 2024
Filed Dec 13 2024 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $238K
945 sh × $251.42
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET